Trial Profile
An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Orteronel (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Takeda Oncology
- 23 Jan 2013 Planned End Date changed from 1 Jun 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 10 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jul 2011 Additional trial centres identified as reported by Barbara Ann Karmanos Cancer Institute record.